Over 1,500 Reports of Adverse Reactions Linked to Anti-Obesity Medications in Ireland
The Health Products Regulatory Authority (HPRA) in Ireland has confirmed that there have been over 1,500 reports of suspected adverse reactions associated with weight loss medications. These reports include a range of side effects, primarily gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. Notably, the HPRA has also documented nine instances where individuals taking anti-obesity injections, specifically semaglutide, liraglutide, or tirzepatide, died; however, they clarified that this does not imply a direct causal relationship between the medications and the fatalities.
These anti-obesity drugs are marketed under various brand names and are authorized as prescription-only medications within the European Union for managing weight and treating Type 2 diabetes. Concerns have been raised by experts regarding the accessibility of these treatments, as many individuals are reportedly obtaining them online without appropriate medical prescriptions. Professor Donal O'Shea, an expert in obesity management, highlighted the risks associated with unsupervised use, noting that patients often lack proper guidance on potential side effects.
Professor O'Shea stated that when these medications are prescribed, healthcare providers typically advise patients on the importance of maintaining hydration and dietary fiber intake to mitigate constipation risks. He emphasized that immediate cessation of the medication is necessary if vomiting occurs. He believes that the reported 1,500 cases likely reflect individuals who are engaged with healthcare practitioners, as these professionals are responsible for reporting to the HPRA. He also mentioned that he has encountered patients in emergency departments experiencing severe side effects, including dizziness and kidney failure, which underscores the real dangers associated with these drugs.
The situation in Ireland mirrors findings in the UK, where reports of adverse reactions have been significantly higher, with approximately 15,000 incidents documented. Given that the UK population is about ten times larger than that of Ireland, these figures suggest a concerning trend regarding the safety of anti-obesity medications.
In a statement, the HPRA explained that the reports it receives are based on healthcare practitioners' suspicions that an adverse experience may be linked to a medication. These are categorized as 'suspected' side effects and are consistent with the known safety profiles of the medications, which are detailed in their product information. All known side effects are included in the product information provided to healthcare professionals and patients, emphasizing the need for informed usage of these treatments.




